Carvedilol phosphate extended-release capsule
Term · Oncology and biomedicine · MLC-T-ONC-012325
An extended-release capsule formulation containing the phosphate salt of carvedilol, a nonselective beta-adrenergic blocking agent with alpha 1-adrenergic blocking activity. Carvedilol is a racemic mixture; the S(-) enantiomer non-selectively binds to and blocks beta-adrenergic receptors, exerting negative inotropic and chronotropic effects, leading to a reduction in cardiac output. Both R(+) and S(-) enantiomers bind to and block alpha 1-adrenergic receptors with equal potency, causing vasodilation and a reduction in peripheral vascular resistance. This agent has no intrinsic sympathomimetic activity.
| Identifier | MLC-T-ONC-012325 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012325",
"term": "Carvedilol phosphate extended-release capsule",
"field": "Oncology and biomedicine",
"definition": "An extended-release capsule formulation containing the phosphate salt of carvedilol, a nonselective beta-adrenergic blocking agent with alpha 1-adrenergic blocking activity. Carvedilol is a racemic mixture; the S(-) enantiomer non-selectively binds to and blocks beta-adrenergic receptors, exerting negative inotropic and chronotropic effects, leading to a reduction in cardiac output. Both R(+) and S(-) enantiomers bind to and block alpha 1-adrenergic receptors with equal potency, causing vasodilation and a reduction in peripheral vascular resistance. This agent has no intrinsic sympathomimetic activity.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/carvedilol-phosphate-extended-release-capsule/"
}
Record 4,292 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.